Injury mechanism of COVID-19-induced cardiac complications.

Ling Leng, Xiu-Wu Bian
Author Information
  1. Ling Leng: Stem Cell and Regenerative Medicine Lab, Department of Medical Science Research Center, State Key Laboratory of Complex Severe and Rare Diseases, Translational Medicine Center, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100730, China.
  2. Xiu-Wu Bian: Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University (Army Medical University), and Key Laboratory of Tumor Immunopathology, Ministry of Education of China, Chongqing 400038, China.

Abstract

Heart dysfunction is one of the most life-threatening organ dysfunctions caused by coronavirus disease 2019 (COVID-19). Myocardial or cardiovascular damage is the most common extrapulmonary organ complication in critically ill patients. Understanding the pathogenesis and pathological characteristics of myocardial and vascular injury is important for improving clinical diagnosis and treatment approach. Herein, the mechanism of direct damage caused by severe acute respiratory syndrome coronavirus 2 to the heart and secondary damage caused by virus-driven inflammation was reviewed. The pathological mechanism of ischemia and hypoxia due to microthrombosis and inflammatory injury as well as the injury mechanism of tissue inflammation and single myocardial cell necrosis triggered by the viral infection of pericytes or macrophages, hypoxia, and energy metabolism disorders were described. The latter can provide a novel diagnosis, treatment, and investigation strategy for heart dysfunctions caused by COVID-19 or the Omicron variant.

Keywords

References

  1. Prog Cardiovasc Dis. 2020 May - Jun;63(3):390-391 [PMID: 32169400]
  2. Eur J Heart Fail. 2020 Nov;22(11):1994-2006 [PMID: 32683753]
  3. J Am Coll Cardiol. 2020 May 12;75(18):2352-2371 [PMID: 32201335]
  4. Arterioscler Thromb Vasc Biol. 2020 Oct;40(10):2404-2407 [PMID: 32762443]
  5. Cardiol Plus. 2021 Oct 1;6(4):199-201 [PMID: 35368976]
  6. Abdom Radiol (NY). 2021 Mar;46(3):1263-1271 [PMID: 32939636]
  7. Stem Cell Reports. 2021 Sep 14;16(9):2274-2288 [PMID: 34403650]
  8. Eur J Heart Fail. 2019 Apr;21(4):425-435 [PMID: 30338885]
  9. Cardiovasc Pathol. 2021 Sep-Oct;54:107361 [PMID: 34174415]
  10. Circ Res. 2021 Apr 16;128(8):1214-1236 [PMID: 33856918]
  11. Lancet. 2020 Aug 1;396(10247):320-332 [PMID: 32682491]
  12. Acta Cardiol. 2021 Apr;76(2):109-124 [PMID: 33208052]
  13. Circulation. 2021 Jan 19;143(3):230-243 [PMID: 33197204]
  14. Lancet Respir Med. 2020 Apr;8(4):420-422 [PMID: 32085846]
  15. Virol J. 2020 Jul 29;17(1):117 [PMID: 32727485]
  16. Sci Transl Med. 2021 Apr 21;13(590): [PMID: 33723017]
  17. Cell Rep. 2022 Jun 14;39(11):110955 [PMID: 35679865]
  18. Eur Heart J. 2020 May 14;41(19):1804-1806 [PMID: 32293672]
  19. Circulation. 2020 Jun 9;141(23):1903-1914 [PMID: 32297796]
  20. Cardiovasc Pathol. 2022 Sep-Oct;60:107447 [PMID: 35718082]
  21. JAMA. 2020 Mar 17;323(11):1061-1069 [PMID: 32031570]
  22. JAMA Cardiol. 2020 Jul 1;5(7):811-818 [PMID: 32219356]
  23. J Am Coll Cardiol. 2020 Jun 23;75(24):3085-3095 [PMID: 32305401]
  24. Int J Infect Dis. 2022 Nov;124:1-10 [PMID: 36075372]
  25. Lancet. 2020 Mar 28;395(10229):1054-1062 [PMID: 32171076]
  26. Arterioscler Thromb Vasc Biol. 2021 Jan;41(1):542-544 [PMID: 33086866]
  27. JACC Basic Transl Sci. 2021 Apr;6(4):331-345 [PMID: 33681537]
  28. Clin Infect Dis. 2017 Jun 01;64(11):1486-1493 [PMID: 28205683]
  29. Cardiovasc Res. 2020 Dec 1;116(14):2177-2184 [PMID: 32750108]
  30. Mediterr J Hematol Infect Dis. 2021 Mar 01;13(1):e2021016 [PMID: 33747397]
  31. Nature. 2022 Mar;603(7902):706-714 [PMID: 35104837]
  32. J Am Coll Cardiol. 2021 Jan 26;77(3):314-325 [PMID: 33478655]
  33. J Thromb Haemost. 2020 Apr;18(4):844-847 [PMID: 32073213]
  34. Heart Rhythm. 2020 Sep;17(9):1463-1471 [PMID: 32387246]
  35. Cardiovasc Res. 2020 Dec 1;116(14):2207-2215 [PMID: 32966582]
  36. Nature. 2002 Jun 20;417(6891):822-8 [PMID: 12075344]
  37. Am J Physiol Heart Circ Physiol. 2020 Nov 1;319(5):H1059-H1068 [PMID: 33036546]
  38. J Med Virol. 2020 Nov;92(11):2409-2411 [PMID: 32516845]
  39. Lancet Microbe. 2020 Oct;1(6):e245-e253 [PMID: 32844161]
  40. Cardiovasc Res. 2007 Jul 1;75(1):29-39 [PMID: 17499227]
  41. Cardiovasc Pathol. 2020 Nov - Dec;49:107263 [PMID: 32784110]
  42. J Clin Invest. 2020 Nov 2;130(11):6151-6157 [PMID: 32759504]
  43. Thorax. 2020 Dec;75(12):1116-1118 [PMID: 32839288]
  44. Eur J Clin Invest. 2009 Jul;39(7):618-25 [PMID: 19453650]
  45. Am J Emerg Med. 2020 Jul;38(7):1504-1507 [PMID: 32317203]
  46. JAMA Cardiol. 2020 Nov 1;5(11):1281-1285 [PMID: 32730555]
  47. Am J Respir Crit Care Med. 2013 Mar 1;187(5):509-17 [PMID: 23348975]
  48. Nature. 2005 Jul 7;436(7047):112-6 [PMID: 16001071]
  49. Proc Natl Acad Sci U S A. 2008 Jun 3;105(22):7809-14 [PMID: 18490652]
  50. JAMA Cardiol. 2020 Jul 1;5(7):802-810 [PMID: 32211816]
  51. Virchows Arch. 2020 Sep;477(3):349-357 [PMID: 32607684]
  52. Nat Rev Immunol. 2020 Jul;20(7):389-391 [PMID: 32439870]
  53. Stem Cell Reports. 2021 Mar 9;16(3):478-492 [PMID: 33657418]
  54. EClinicalMedicine. 2020 Jun 25;24:100434 [PMID: 32766543]
  55. Lancet Respir Med. 2020 Jul;8(7):681-686 [PMID: 32473124]
  56. Biomedicines. 2020 Dec 18;8(12): [PMID: 33352880]
  57. Clin Microbiol Infect. 2022 Aug;28(8):1066-1075 [PMID: 35339672]
  58. Ann Intern Med. 2020 Dec 15;173(12):1030 [PMID: 33316197]
  59. Eur J Heart Fail. 2019 Aug;21(8):965-973 [PMID: 31087601]
  60. Cardiovasc Pathol. 2021 Jan - Feb;50:107300 [PMID: 33132119]
  61. Lancet. 2020 Feb 15;395(10223):497-506 [PMID: 31986264]
  62. Signal Transduct Target Ther. 2021 Jul 7;6(1):255 [PMID: 34234112]
  63. Eur Heart J. 2020 Oct 14;41(39):3827-3835 [PMID: 32968776]
  64. Lancet Microbe. 2020 Nov;1(7):e290-e299 [PMID: 33015653]
  65. Eur J Heart Fail. 2020 May;22(5):911-915 [PMID: 32275347]
  66. Cardiovasc Res. 2020 Aug 1;116(10):1733-1741 [PMID: 32638018]
  67. Int J Legal Med. 2021 Mar;135(2):577-581 [PMID: 33392658]
  68. Circulation. 2020 May 19;141(20):1648-1655 [PMID: 32200663]
  69. Biochem Pharmacol. 2020 Aug;178:114114 [PMID: 32579957]
  70. Lancet Child Adolesc Health. 2020 Oct;4(10):790-794 [PMID: 32828177]
  71. Am J Physiol Lung Cell Mol Physiol. 2018 Jan 01;314(1):L17-L31 [PMID: 28935640]
  72. Lancet. 2020 Mar 28;395(10229):1033-1034 [PMID: 32192578]
  73. Circulation. 2020 Sep 15;142(11):1123-1125 [PMID: 32689809]
  74. Circulation. 2020 Aug 18;142(7):708-710 [PMID: 32795091]
  75. Cytokine Growth Factor Rev. 2021 Apr;58:30-31 [PMID: 32873506]
  76. Proc Natl Acad Sci U S A. 2021 Apr 20;118(16): [PMID: 33811184]
  77. Virus Res. 2008 Sep;136(1-2):8-15 [PMID: 18554741]
  78. Mod Pathol. 2020 Jun;33(6):1007-1014 [PMID: 32291399]
  79. Infect Drug Resist. 2022 Mar 22;15:1175-1189 [PMID: 35345472]
  80. Cardiovasc Res. 2020 Aug 1;116(10):1666-1687 [PMID: 32352535]

Word Cloud

Created with Highcharts 10.0.0causedmechanismCOVID-19damageinjuryorgandysfunctionscoronaviruspathologicalmyocardialdiagnosistreatmentheartinflammationhypoxiaHeartdysfunctiononelife-threateningdisease2019MyocardialcardiovascularcommonextrapulmonarycomplicationcriticallyillpatientsUnderstandingpathogenesischaracteristicsvascularimportantimprovingclinicalapproachHereindirectsevereacuterespiratorysyndrome2secondaryvirus-drivenreviewedischemiaduemicrothrombosisinflammatorywelltissuesinglecellnecrosistriggeredviralinfectionpericytesmacrophagesenergymetabolismdisordersdescribedlattercanprovidenovelinvestigationstrategyOmicronvariantInjuryCOVID-19-inducedcardiaccomplicationsCardiovasculardiseasesMolecularpathologySARS-CoV-2

Similar Articles

Cited By